Mallinckrodt acquires skin substitute company Stratatech
Mallinckrodt PLC acquired privately held regenerative medicine company Stratatech Corp. (cell-based skin substitute). Stratatech's progenitor keratinocyte (the predominant cell type in the skin's outermost layer, the epidermis) tissue-engineering technology produces living tissues designed to mimic human skin and promote tissue regeneration.
- Medical Devices
- Research, Analytical Equipment & Supplies
- Gene Therapy, Cell Therapy
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.